Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Fig. 3

Therapies received among patients who received EGFR-TKI in first line and were tested for EGFR T790M.

1 L: first line; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor.

a Patients still treated with their first EGFR-TKI therapy in the month prior to data cutoff were considered as remaining on EGFR-TKI therapy.

b Targeted therapies included EGFR-TKIs, monoclonal antibody inhibitors, ALK inhibitors, and angiogenesis inhibitors.

c The proportion of patients who received afatinib, erlotinib and osimertinib are calculated over the total number of patients in the subgroup (e.g. the 97 patients for the analysis of patients not tested for EGFR T790M).

Back to article page